Market closed

Gilead Sciences/$GILD

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Ticker

$GILD

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Foster City, United States

Employees

18,000

Website

www.gilead.com

Gilead Sciences Metrics

BasicAdvanced

$113B

937.09 $0.10

0.19 $3.08

3.38%

Price and volume

Market cap

$113B

Beta

0.19

52-week high

$96.30

52-week low

$62.07

Average daily volume

6.6M

Dividend rate

$3.08

Financial strength

Current ratio

1.114

Quick ratio

0.821

Long term debt to equity

116.562

Total debt to equity

126.415

Dividend payout ratio (TTM)

3,085.71%

Interest coverage (TTM)

11.51%

Management effectiveness

Return on assets (TTM)

12.06%

Return on equity (TTM)

0.56%

Valuation

Price to earnings (TTM)

937.091

Price to revenue (TTM)

4.008

Price to book

6.14

Price to tangible book (TTM)

-10.92

Price to free cash flow (TTM)

12.028

Dividend yield (TTM)

3.38%

Forward dividend yield

3.38%

Growth

Revenue change (TTM)

3.31%

Earnings per share change (TTM)

-97.92%

3-year revenue growth (CAGR)

0.98%

3-year earnings per share growth (CAGR)

-74.48%

3-year dividend per share growth (CAGR)

2.88%

What the Analysts think about Gilead Sciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.

Gilead Sciences Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Gilead Sciences Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Gilead Sciences News

AllArticlesVideos

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Seeking Alpha·2 days ago

Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)

Seeking Alpha·2 days ago

Gilead CEO on funding for new HIV prevention medicine

CNBC Television·2 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GILD

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Gilead Sciences stock?

Gilead Sciences (GILD) has a market cap of $113B as of January 15, 2025.

What is the P/E ratio for Gilead Sciences stock?

The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 937.09 as of January 15, 2025.

Does Gilead Sciences stock pay dividends?

Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of January 15, 2025, the dividend rate is $3.08 and the yield is 3.38%. Gilead Sciences has a payout ratio of 3085.71% on a trailing twelve-month basis.

When is the next Gilead Sciences dividend payment date?

The next Gilead Sciences (GILD) dividend payment date is unconfirmed.

What is the beta indicator for Gilead Sciences?

Gilead Sciences (GILD) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.